Bruker has announced a majority investment in RECIPE Chemicals + Instruments, based in Munich, Germany, to enhance its diagnostic capabilities.
RECIPE specialises in vendor-agnostic therapeutic drug monitoring (TDM) and clinical in vitro diagnostic kits for LC-MS/MS, HPLC, and ICP-MS assays.
With more than 40 years of experience and 60 employees, RECIPE is highly profitable, projecting 2024 revenues exceeding $15m.
The collaboration aims to enhance Bruker’s small-molecule clinical diagnostic assays.
It will integrate RECIPE’s ClinMASS kits with Bruker’s EVOQ liquid chromatography triple-quadrupole mass spectrometers, along with LC-TQ-MS systems by other vendors.
Bruker applied mass spectrometry senior vice president Jeffrey Zonderman said: “We are excited to welcome RECIPE to the Bruker family.
“The majority investment aligns with our strategic vision for LC-TQ-MS assays, enhanced with novel chrom-free assays based on our proprietary DART technology to lead in clinical research and regulated TDM markets.
“The RECIPE ClinMASS and novel ClinDART assays, combined with LC or chrom-free EVOQ DART-TQ⁺ methods, are expected to offer unparalleled flexibility, throughput and cost-effectiveness.”
Also, the two companies are preparing to introduce high-throughput, chromatography-free ClinDART kits on EVOQ-DART TQ⁺ systems.
The kits are anticipated to offer flexibility between established LC-TQ-MS methods and novel high-throughput ClinDART workflows.
In chrom-free mode, the EVOQ-DART TQ⁺ provides higher throughput for multiplex assays without chromatography, with triple-quad MS selectivity and multiple-reaction monitoring capabilities.
The ClinDART platform also enhances sustainability with a 95% reduction in solvent use, lower costs, and increased laboratory productivity.
RECIPE managing director Gernot Wolfram said: “Bruker’s majority investment in RECIPE and our planned joint introduction of high-throughput ClinDART assays represents a significant advancement in clinical mass spectrometry.
“Our unique collaboration on chrom-free, triple-quad TDM assays will allow RECIPE to provide clinical laboratories with a powerful new tool that complements our well-regarded ClinMASS workflows on the EVOQ-DART TQ⁺.
“The additional high-throughput ClinDART methods reduce operating costs, and accelerate time-to-market for newly developed clinical diagnostics and multiplexed drugs of abuse screening assays.”
Earlier this year, Bruker launched the X4 POSEIDON, a high-performance 3D X-ray microscope using micro-Computed Tomography (microCT).
The benchtop system offers advanced capabilities similar to larger systems, making high-resolution 3D X-ray microscopy accessible for industrial applications and scientific research.
It features a high-end X-ray source that significantly improves 3D resolution.
Also, the system comes with a large field-of-view high-efficiency detector, which can be paired with a high-resolution scientific CMOS detector for analytical flexibility.
It is powered by 3DxSUITE software, offering automated protocols, an intuitive user interface, and multi-language support.
